The purpose of the #ASPRIA trial is to determine if a combination of two drugs, #Atezolizumab and #SacituzumabGovitecan, can be used to prevent recurrence in #TripleNegativeBreastCancer.
For more information call 877-338-7425 or visit:
www.dana-farber.org/clinical-tri...
#BreastCancer #TNBC